Vicarious Surgical

Vicarious Surgical, Inc. engages in advancing the field of surgical robotics. Through the use of surgical robotics, the company aims to improve patients lives, surgeons abilities, and expand global access to high-quality care. The company was founded by Adam Sachs and Sammy Khalifa on May 6, 2020 and is headquartered in Waltham, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vicarious Surgical reports progress in procedures and system development

Vicarious Surgical demonstrated strong performance in Q4 2022 with successful procedures and system advancements.
While facing financial challenges, the company's strategic strengths and opportunities position them for future growth.
Maintaining a balance between innovation, cost management, and regulatory milestones will be key for Vicarious Surgical.

Vicarious Surgical reports Q1 progress amidst regulatory discussions and innovation

Vicarious Surgical's Q1 2023 performance reflects progress in refining their robotic system and managing expenses, with a strong cash position and ongoing FDA discussions.
The company's strengths lie in innovation, regulatory focus, and strategic spending, positioning them well for future growth and expansion into new indications.
Challenges include high operating expenses and regulatory uncertainties, while opportunities exist in enhancing their technology and capitalizing on market potential through disciplined investments.

Vicarious Surgical reports Q2 loss, eyes FDA milestones for growth

Vicarious Surgical's Q2 performance reflects a focus on innovation, regulatory compliance, and strategic leadership.
The company's strong cash position, upcoming milestones, and product development efforts signal growth potential.
Challenges in managing expenses, regulatory hurdles, and market competition require careful navigation and strategic planning.
Opportunities lie in expanding partnerships, FDA approvals, and leveraging the demand for minimally invasive surgical solutions.

Vicarious Surgical reports improved finances but faces delays in flagship program

Vicarious Surgical navigated challenges with financial improvements but faces delays in their flagship program. Despite setbacks, the company remains committed to revolutionizing robotic surgery and enhancing capital efficiency.

Vicarious Surgical reports progress in product development and funding

Vicarious Surgical navigated challenges in 2023, strengthened its product offering, and secured funding for future growth. The company's financial position is stable, with a focus on achieving milestones in 2024. Leveraging partnerships and regulatory clarity present growth opportunities.

Vicarious Surgical reports strong Q1 performance and eyes global expansion

Vicarious Surgical's Q1 2024 performance reflects financial improvements and technological advancements, positioning the company for future growth.
While facing challenges in system integration and regulatory processes, the company's strengths in technology innovation and leadership provide a strong foundation for success.
Opportunities in international expansion, strategic partnerships, and regulatory advancements present avenues for Vicarious Surgical to capitalize on its unique market position and drive long-term value.

Vicarious Surgical reports Q2 progress amidst financial challenges

Vicarious Surgical's Q2 2024 performance showed progress in system integration and partnerships, but also highlighted financial challenges.
The company's strong cash position and focus on upcoming milestones position it well for future growth opportunities.
Analyst questions underscore the need for Vicarious Surgical to address financial concerns and execute on its strategic initiatives effectively.

Vicarious Surgical reports improved financials and progresses on robotic platform

Vicarious Surgical's Q3 2024 performance showed financial improvements and progress in developing its single-port platform for robotic surgery. While challenges and uncertainties exist, the company's focus on cost management and regulatory readiness bode well for future growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vicarious Surgical, Inc. a blank check company, which engages in effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It also designs surgical robotics. The company was founded by Adam Sachs, Sammy Khalifa, and Barry Greene on May 1, 2014 and is headquartered in Waltham, MA.

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the pending departure of William Kelly, its Chief Financial Officer (CFO), to pursue other career opportunities, after nearly four years of dedicated service with the Company. Mr. Kelly has served as Vicarious Surgical's CFO since January 2021. He will assist.

Vicarious Surgical Announces Departure of Chief Financial Officer

Vicarious Surgical Inc. (NYSE:RBOT ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Kaitlyn Brosco – Director-Investor Relations Adam Sachs – Co-Founder and Chief Executive Officer Bill Kelly – Chief Financial Officer Conference Call Participants Adam Maeder – Piper Sandler Operator Hello, everyone, and welcome to Vicarious Surgical's Third Quarter 2024 Earnings Call. My name is Lydia and I'll be your operator today.

Vicarious Surgical Inc. (RBOT) Q3 2024 Earnings Call Transcript

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the quarter ended September 30, 2024. Management will host a corresponding conference call at 4:30 p.m. ET today, November 12, 2024. “Our team's strong execution throughout the year, continuing in the third quarter, has us on track to ac.

Vicarious Surgical Reports Third Quarter 2024 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced it will report financial results for the third quarter ended September 30, 2024 after the market closes on Tuesday, November 12, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in li.

Vicarious Surgical to Report Third Quarter 2024 Financial Results on November 12, 2024

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the Company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Management is scheduled to present in a fireside chat on Friday, September 6, 2024 at 11:30 a.m. ET. About Vicarious Surgical Founded in 2014, Vicarious S.

Vicarious Surgical to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Vicarious Surgical Inc (NYSE:RBOT ) Q2 2024 Results Conference Call August 12, 2024 4:30 PM ET Company Participants Kaitlyn Brosco - IR Bill Kelly - CFO & Treasurer Adam Sachs - Co-Founder, CEO & Director Conference Call Participants Eric Anderson - TD Cowen Andrew Ranieri - Morgan Stanley Ryan Zimmerman - BTIG Operator Good afternoon. Thank you for attending the Vicarious Surgical's 2024 Second Quarter Earnings Call.

Vicarious Surgical Inc (RBOT) Q2 2024 Earnings Call Transcript

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced financial results for the quarter ended June 30, 2024. Management will host a corresponding conference call at 4:30 p.m. ET today, August 12, 2024. “Our team's effective execution of our development plans during the first half of this year has positioned us w.

Vicarious Surgical Reports Second Quarter 2024 Financial Results

Vicarious Surgical (RBOT) teams up with LSU Health New Orleans to advance its V1.0 surgical robot. It aims to file for FDA approval by 2026.

Vicarious Surgical (RBOT) Partners LSU Health New Orleans

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that it has signed a strategic development agreement with the LSU Health New Orleans. LSU Health New Orleans is Louisiana's flagship and most comprehensive academic health sciences center. Known for the quality of its academic and training programs, the cente.

Vicarious Surgical Announces New Hospital System Partnership with LSU Health New Orleans

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives through the transformation of surgical robotics, today announced it will report financial results for the second quarter ended June 30, 2024 after the market closes on Monday, August 12, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interes.

Vicarious Surgical to Report Second Quarter 2024 Financial Results on August 12, 2024

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives through the transformation of surgical robotics, today announced it will effect a 1-for-30 reverse stock split of the Company's issued and outstanding Class A common stock, par value $0.0001 per share, and Class B common stock, par value $0.0001 per share. The reverse stock split was approved by Vicarious S.

Vicarious Surgical Announces Reverse Stock Split

Vicarious Surgical (NYSE: RBOT ) just reported results for the first quarter of 2024. Vicarious Surgical reported earnings per share of -9 cents.

RBOT Stock Earnings: Vicarious Surgical Meets EPS for Q1 2024

Vicarious Surgical Inc. (NYSE:RBOT ) Q1 2024 Earnings Conference Call April 29, 2024 4:30 PM ET Company Participants Kaitlyn Brosco - Head, Investor Relations Adam Sachs - Co-Founder and CEO Bill Kelly - Chief Financial Officer Randy Clark - President Conference Call Participants Ryan Zimmerman - BTIG Adam Maeder - Piper Sandler Josh Jennings - TD Cowen Operator Hello. And welcome to Vicarious Surgical's 2024 First Quarter Earnings Call.

Vicarious Surgical Inc. (RBOT) Q1 2024 Earnings Call Transcript

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives through the transformation of surgical robotics, today announced financial results for the quarter ended March 31, 2024. Management will host a corresponding conference call at 4:30 p.m. ET today, April 29, 2024. “I'm proud to report a productive start to 2024 as we advance our mission to improve lives by t.

Vicarious Surgical Reports First Quarter 2024 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it will report financial results for the first quarter ended March 31, 2024 after the market closes on Monday, April 29, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in l.

Vicarious Surgical to Report First Quarter 2024 Financial Results on April 29, 2024

Vicarious Surgical Inc. (NYSE:RBOT ) Q4 2023 Earnings Conference Call March 4, 2024 4:30 PM ET Company Participants Kaitlyn Brosco - IR Adam Sachs - CEO William Kelly - CFO Conference Call Participants Ryan Zimmerman - BTIG Operator Good afternoon, and welcome to Vicarious Surgical's Fourth Quarter 2023 Earnings Conference Call. My name is Matt, and I'll be your operator for today's call.

Vicarious Surgical Inc. (RBOT) Q4 2023 Earnings Call Transcript

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter and full year ended December 31, 2023. Management will host a corresponding conference call at 4:30 p.m. ET today, March 4, 2024. “We made meaningful progress transitioning our Beta 2.

Vicarious Surgical Reports Fourth Quarter and Full Year 2023 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced the Company will participate in the TD Cowen 44th Annual Healthcare Conference. Management is scheduled to present on Tuesday, March 5, 2024 at 2:10 p.m. ET. A live webcast of the presentation will be accessible to th.

Vicarious Surgical to Participate in TD Cowen's 44th Annual Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it will report financial results for the fourth quarter and full year ended December 31, 2023 after the market closes on Monday, March 4, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investor.

Vicarious Surgical to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced that Randy Clark has been appointed President effective today, January 29, 2024. As Vicarious Surgical prepares for its next phase of growth following the anticipated finalization of the Vicarious Surgical Version 1.0.

Vicarious Surgical Strengthens Executive Team with Appointment of Randy Clark as Company President

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced the Company will present at the Piper Sandler 35th Annual Healthcare Conference. Management is scheduled to participate in a fireside chat on Tuesday, November 28, 2023, at 9:00 am ET. Interested parties can access a.

Vicarious Surgical to Present at the Piper Sandler 35th Annual Healthcare Conference

Vicarious Surgical Inc. (NYSE:RBOT ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Kaitlyn Brosco - Investor Relations Adam Sachs - Chief Executive Officer Bill Kelly - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Adam Maeder - Piper Sandler Josh Jennings - TD Cohen Caitlin Cronin - Canaccord Genuity Operator Good afternoon, and welcome to Vicarious Surgical's Third Quarter 2023 Earnings Conference Call. My name is Kate, and I'll be your operator for today's call.

Vicarious Surgical Inc. (RBOT) Q3 2023 Earnings Call Transcript

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter ended September 30, 2023. Management will host a corresponding conference call at 4:30 p.m. ET today, November 13, 2023. “The third quarter brought several successes for our business,.

Vicarious Surgical Reports Third Quarter 2023 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it will report financial results for the third quarter ended September 30, 2023, after the market closes on November 13, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in l.

Vicarious Surgical to Report Third Quarter 2023 Financial Results on November 13, 2023

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced that on September 20, 2023, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average clo.

News for Vicarious Surgical Stock (RBOT)